These include patients with inflammatory carcinoma, locally advanced carcinoma, occult carcinoma, or patients with persistent findings of suspicious pathological nodes after NAC according to ultrasound examination, especially in the tumor phenotypes HER2-positive and triple-negative breast cancer. This evidence concerns the gene ERBB2 and carcinoma.